INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

AI and Future of Drug Discovery: Innovation, Ethics and Impact

Rupendra Doshi*[1], Manoj Phadtare[2], Maitrayi Salunkhe[3], Tejaswini Govekar[4], Aishwarya Gosavi[5], Priyanka Parekar[6]

[1,3,4,5] *Sou. Venutai chavan pharmacy college, Phaltan, Maharashtra, India, 415523*
[2] *Lords university, Alwar Rajasthan, India,301028*
[6] *Karmyogi college of Pharmacy, Pandharpur, Dist- Solapur, Maharashtra, India 413304*

ARTICLE INFO

Published: 9 Mar 2026
Keywords:
Artificial Intelligence, Drug Discovery, Machine Learning, Deep Learning, Graph Neural Networks Large Language Models, Drug Repurposing, Target Identification, Lead Optimization
DOI:
10.5281/zenodo.18925722

ABSTRACT

The integration of artificial intelligence into drug discovery is revolutionizing the pharmaceutical landscape by addressing longstanding challenges such as high cost, prolonged timelines, and elevated failure rates. Traditional drug development processes often involve labor-intensive methods, including high-throughput screening and trial-and-error research, which can be time consuming and resource draining. In contrast, AI technologies, particularly machine learning and deep learning, offer the potential to significantly accelerate various stages of drug discovery. These AI driven approaches facilitates the rapid analysis of vast database, enabling the identification of novel drug targets, optimization of lead compounds and prediction of pharmacokinetics and toxicology properties with unprecedented accuracy. Innovative application of AI, such as graph neural networks and large language models are further enhancing the drug discovery process. GNMs for instance, excel in modeling molecular structures and properties, while LLMs assist in synthesizing and interpreting complex biomedical literature, thereby streamlining the identification of potential therapeutic candidates. Moreover, AI role extends to the design of clinical trials, where it aids in patient satisfaction, biomarker discovery and the simulation of trial outcomes, thereby improving efficiency and success rates. Despite these advancement, the adoption of AI in drug discovery is not without challenges. Issues related to data quality, model interpretability and regulatory acceptance remain significant hurdles. The reliance on large, high quality datasets is crucial, as biased or incomplete data can lead to inaccurate predictions and hinder the generalizability of AI models. Additionally, the black box nature of many AI algorithm complicates the understanding of decision making processes, raising concerns among stakeholders regarding transparency and trust. Looking forward, the future of AI drug discovery is promising. Emerging trends suggest a move towards more explainable AI models, integration of multi-omics data and the

***Corresponding Author:** Rupendra Doshi
Address: *Sou. Venutai chavan pharmacy college, Phaltan, Maharashtra, India, 415523.*
Email ✉: rupdoshi@rediffmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

development of federated learning techniques that allow for collaborative data analysis without compromising privacy. Furthermore, advancement in AI are expected to facilitate the discovery of treatments for complex and rare diseases, thereby broadening the therapeutics landscape. As these technologies continue to evolve, AI is poised to play a pivotal role in transforming drug discovery into a more efficient, cost-effective and patient centric endeavor.

INTRODUCTION

Development of new pharmaceutical product is known as drug. Traditionally drug discovery involve years of research, trial-error experiment and very high cost. This multi-step process includes selecting the disease, large scale screening test which helps identifying HIT molecule and further a molecule chosen that binds specifically and selectively to the target. After successful screening of the drug it moves into preclinical and clinical phases. After trials the drug must be approved by regulatory bodies such as food and drug administration (FDA) or Europe medicine agency (EMA). The drug's safety will continue to be monitored through pharmacovigilance throughout its distribution after release in market. A drug takes decade or more to reach patient and can cost a lot money to develop. Many ideas don't become real medicines because of unexpected problems.[1]

1. IMPORTANCE IN DRUG DISCOVERY:

AI is rapidly transforming drug discovery by accelerating target identification, enabling large-scale virtual screening and designing novel molecules that would be impractical to find by classical approaches; these capabilities shorten early stage timelines and increase the diversity of candidate compounds entering preclinical testing. The integration of AI into drug discovery has emerged a transformative shift in pharmaceutical research, significantly reducing both time and cost. AI methods such as machines learning, deep learning and generative model can analyze large biomedical and chemical dataset to identify promising targets, predict molecular properties, design novel compounds de novo, and optimize leads more efficiently than conventional approaches. As a result ai is not merely a supplementary too; but increasingly a center pillar in accelerating drug discovery, enhancing success rates, and enabling therapies that might otherwise remain unrealized [2].

2. CONVENTIONAL METHOD:

Conventional drug discovery typically begins with target identification and validation followed by high-throughput screening of large compounds libraries to find initial "hits" which are then refined through lead and lead optimization phases using in vitro, in vivo, and biochemical assays. HTS allows screening of tens or hundreds of thousands of compounds per day using automated platforms and assay readout such as fluorescence or enzyme inhibition, but it suffers from high rates of false positive/negative, large resources demands, and limited ability to access ADME and toxicity early on. In vitro systems are used to probe target engagement, cytotoxicity and metabolic stability while in vivo animal models provide insights on pharmacokinetics, safety and efficacy but these are expensive, time-consuming and may not always translate well to humans [3,4].

3. INNOVATIVE APPLICATIONS IN DRUG DISCOVERY:

Recent innovations in AI have begun to reshape drug discovery by enabling capabilities that were previously infeasible or extremely resource-intensive. One such advance is de novo drug design, where generative models propose entirely new molecular structure optimized for multiple criteria such as target binding, ADME properties and synthetize ability – moving beyond reliance on

existing chemical libraries. Also hybrid quantum classical models are being explored to generate molecules with improved physiochemical profiles using fewer parameters and reduced computational cost. Moreover, AI is being used to improve scoring functions and virtual screening by using deep learning methods that outperform traditional scoring in recognizing binding affinities and predicting ADMET traits. Finally, there is growing use of AI in natural product drug discovery and drug repurposing- using AI driven network approaches, multimodal deep learning and algorithms that comb through multiomics data combined with similarity or fusion methods to find new uses for existing molecules, or to identify bioactive components in complex natural extract [5-7].

4. ADVANTAGES:

Ai considerably accelerate and enhances various stages of drug discovery. It can reduce the time and cost associated with target identification, hit discovery and lead optimization by leveraging predictive modeling, virtual screening and generative chemistry. For instance, AI enables more accurate ADMET predictions, reducing failure in later stages. It also facilities exploration of novel chemical space beyond known scaffolds and supports personalized medicine by integrating patient, omics and phenotypic data. Another key benefit is that AI offers scalability in screening large compound libraries in silico, reducing the reliance on expensive experimental assay. AI offers transformative advantages in drug discovery by boosting efficiency, accuracy, and innovation. The use of AI in structuring clinical trials also has shown promise in reducing trial durations, costs and improving statistical power [8-10].

5. DISADVANTAGES:

Benefits come with significant disadvantages. A major challenge is data quality, availability and bias: datasets are often limited, inconsistent, non-representative of all relevant populations or incomplete. This undermines generalizability of models and can lead to unfair or unsafe predictions. The black box nature of many learning models poses difficulties for interpretability and transparency which are important for regulatory acceptance, clinical trust and diagnosing unexpected behavior.[11-14] Further, translating in silico or computational predictions into effective in vitro, in vivo and eventually human clinical trial results remain non trivial: some molecules predicted to be optimal computationally may be hard to synthesis, may fail due to unforeseen toxicity, pharmacokinetics or biological factors not captured by the model. Regulatory, ethical and infrastructural hurdles are also significant: uses of patient data privacy, informed consent, intellectual property, legal framework for AI-derived discoveries, and access to high compute resources are often cited as constraints. Finally, over-reliance on retrospective benchmarks and overfitting is a concern. Some AI models perform well on existing databases but may not generalize to new, unseen real-world scenarios or prospective trials [15-19].

6. FUTURE SCOPE:

As AI continues to mature, its future role in drug discovery looks poised for even greater transformation. One major direction is the deeper use of graph neutral networks and other structure-aware models to more to chemical interactions; recent review suggest these will be important not just for property prediction but also for generative tasks, uncertainty quantification, and scalability across large chemicals spaces. In parallel, Large Language Models are being explored for their potential to interpret complex biochemical

literature, suggest hypotheses for disease mechanism, propose novel targets, assists in biomarker discovery, and even help with designing mechanism, and even help with designing clinical trials via better capturing semantics of trial protocols and patient data. Meanwhile, the recent review "future of pharmaceuticals: [20-22] AI in drug discovery and development" points out that AI is expected to further reduce timelines and costs, improve success rates and facilitates more personalized medicines, especially as data sources become richer and models more robust [23].

7. CONCLUSION:

AI holds immense promise to reshape the landscape of drug discovery by complementing and in many cases surpassing traditional methods. Where conventional approaches depends heavily on brute-force experimentation, resources-intensive high-throughput screening and lengthy trial and error cycles, AI techniques offer speed, predictive power and the ability to explore chemicals and biological spaces far more broadly and intelligently. Through virtual screening, generative molecular design, predictive ADMET modelling and AI-assisted clinical trial strategies, many bottlenecks in the pipeline can be ameliorated. However, these benefits do not come without challenges: the success of AI is tightly linked to the availability of large, high-quality and diverse datasets; the black box nature of many models hinders interpretability and trust; and regulatory, ethical, and translational barriers remain formidable. The future success of AI in drug discovery will likely rest on hybrid strategies-tightly integrating AI with wet-lab validation and on advances in explain ability, federated and privacy-preserving methods, multi- omics integration, and cross-disciplinary collaboration. If these front liners are navigated well, AI could dramatically reduce the time, cost and risk associated with bringing new therapeutics to patients, ultimately democratizing innovation and accelerating progress against complex disease [24].

REFERENCES

1. Blanco-gonzale A., et AI., The role of AI in drug discovery: challenges and opportunities – comprehensive review on AI across discovery stages.
2. ferreira F.J.N., AI driven drug discovery : A comprehensive review (2025, PMC)- recent review covering 2019-2024 advances.
3. jumper J., et al., Highly accurate protein structure prediction with Alphafold - Nature 2021 (landmark protein- structure AI)
4. Nature news: major Alphafold upgrade offers boost for drug discovery – review of Alphafold impact and follow on development (may 2024)
5. Santos-junior C.D., et al., discovery of antimicrobial peptides in the global microbiome – cell 2024
6. U.S. food and drug administration , Artificial intelligence for drug development / considerations for use of AI to support regulatory decision making agency pages and draft guideline on AI credibility and regulatory consideration(2024-25)
7. kim, H., et al., "artificial intelligence in drug design and discovery" a comprehensive review. PMC,2023
8. Bai, F., et al. "AI enhances drug discovery and development." PMC,2023
9. Jimenze-luna, J., et al. "Artificial intelligence in drug discovery: recent advances." Tandfonline, 2021
10. Bhat, A.R., et al. "artificial intelligence in drug design and discovery." Science direct, 2025

11. Sabry, Z., et al. "AI driven drug discovery and repurposing using multi-omics." Exploration Pub,2025
12. Lin, M., et al." Medicine learning and multi-omics integration." Translational medicine,2025
13. The annual review article "Artificial intelligence for drug discovery: Are we there yet? (2024)
14. Lloyd, M.D., et al. "High throughput screening for the discovery of enzyme Inhibitor''. Journal of medicinal chemistry, 2020,63(19),pp. 10742-10772
15. Hit discovery and hit to lead approaches. Drug discovery today, volume 11, issues 15-16, august 2006, pages 714-748
16. Martis, E. A., Radhakrishnan, r., badve, r.r. "review article : High-throughput screening: the hits and leads of drug discovery- an overview." Journal of applied pharmaceutical science, 2011 mar;1(1):2-10
17. In vitro and in vivo models; in vitro and in vivo approaches for screening the potential of anticancer agent : A review. Pubmed,2022
18. Recent development in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. PMC,2021
19. Integral artificial intelligence in drug discovery and early drug development: a transformative approach. Bio-maker research. 2025-role of AI in de novo design, scoring functions, etc.
20. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Springer, 2025.
21. Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomaker research, 2025
22. AI-driven drug discovery: A comprehensive review, PMC an article.
23. Artificial intelligence as a tool in drug discovery and development. PMC article
24. Data centric challenges with the application and adoption of artificial intelligence for drug discovery. Ghislat, Hernandez, piyawajanusorn, Ballester,2024

HOW TO CITE: Rupendra Doshi, Manoj Phadtare, Maitrayi Salunkhe, Tejaswini Govekar, Aishwarya Gosavi, Priyanka Parekar, AI and Future of Drug Discovery: Innovation, Ethics and Impact, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 3, 907-911. https://doi.org/10.5281/zenodo.18925722